A practical map of where longevity claims sit today: frontier risk, commercial claims, serious-but-unproven drugs, measurement claims and clinic services.
Peptides, gene therapy and senolytics where internet demand is ahead of human evidence.
No strong human evidence shows that BPC-157 heals tendon or ligament injuries. Most support is animal, cell or mechanism-based, and internet recovery claims should not be treated as proven clinical benefit.
TB-500 injury-recovery claims are not supported by strong human clinical evidence. The claim often relies on extrapolation from thymosin beta-4 biology and should be treated as unproven.
Semax has been discussed in non-US medical and research contexts, but that does not prove it improves cognition in healthy people. Healthy-user nootropic claims remain unproven.
Epitalon is not proven to extend human lifespan. Longevity claims rely on early or indirect evidence and should not be treated as established anti-aging medicine.
GHK-Cu has some cosmetic and mechanistic skin-interest signals, but broad reversal claims are too strong. Topical cosmetic context is different from injectable or research-use promotion.
MOTS-c is biologically interesting, but human metabolism and longevity claims remain unproven. Do not treat mitochondrial mechanism as clinical proof.
Partial reprogramming is one of the most important frontier ideas in aging biology, but it has not been proven to reverse human aging.
OSK gene therapy is not an available, proven anti-aging treatment for consumers. Claims suggesting current consumer age-reversal availability are misleading and high-risk.
Fisetin has senolytic interest from preclinical research, but it is not proven to clear senescent cells in humans in a way that improves aging outcomes.
Dasatinib plus quercetin should not be treated as a DIY longevity routine. Dasatinib is a prescription oncology drug, and senolytic research does not justify self-directed use.
Prescription-drug candidates with real biology but unresolved human aging endpoints.
Rapamycin has unusually strong aging-biology interest, but it is not proven to slow human aging or extend lifespan in healthy adults. Off-label longevity use remains a medical decision, not a protocol from an article.
Metformin is an important diabetes drug and longevity candidate, but it is not proven to extend lifespan in healthy non-diabetic adults.
Acarbose has interesting animal longevity signals, but it is not proven as a longevity drug for healthy humans.
NAD and senolytic supplement claims where biomarkers, marketing and outcomes are often blurred.
NMN may affect NAD-related biomarkers in some studies, but that does not prove it slows human aging. The stronger claim needs clinical outcomes, not only a molecule-level signal.
There is no simple evidence-based winner between NR and NMN for longevity. Comparisons depend on dose form, endpoints, product quality and whether the outcome is a biomarker or a health result.
Biological-age and biomarker claims where a number is often overinterpreted.
Epigenetic clocks can be useful research tools and risk markers, but they do not tell an individual exactly how long they will live.
A biological-age result can be a tracking signal, but it does not by itself prove that a protocol is working or improving long-term health.
Paid services that package plausible biology into stronger consumer outcomes.
NAD IV anti-aging claims are not supported by strong evidence. Infusion marketing often uses cellular language that does not prove meaningful aging outcomes.